Hypoxia-Targeted Dose Painting in Radiotherapy

被引:6
|
作者
Salem, Ahmed [1 ,2 ,3 ]
机构
[1] Hashemite Univ, Fac Med, Dept Anat Physiol & Biochem, Zarqa, Jordan
[2] Univ Manchester, Div Canc Sci, Manchester, England
[3] Hashemite Univ, Fac Med, Dept Anat Physiol & Biochem, Zarqa, Jordan
关键词
CELL LUNG-CANCER; RANDOMIZED PHASE-II; LOCALLY ADVANCED HEAD; TUMOR HYPOXIA; NECK-CANCER; F-18-FLUOROMISONIDAZOLE PET; MULTIPARAMETRIC-MRI; RADIATION-THERAPY; OPEN-LABEL; CARCINOMA;
D O I
10.1016/j.semradonc.2023.03.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hypoxia (oxygen deprivation) occurs in most solid malignancies, albeit with considerable heterogeneity. Hypoxia is associated with an aggressive cancer phenotype by promotion of genomic instability, evasion of anti-cancer therapies including radiotherapy and enhancement of metastatic risk. Therefore, hypoxia results in poor cancer outcomes. Targeting hypoxia to improve cancer outcomes is an attractive therapeutic strategy. Hypoxia-targeted dose painting escalates radiotherapy dose to hypoxic sub-volumes, as quantified and spatially mapped using hypoxia imaging. This therapeutic approach could overcome hypoxia-induced radioresistance and improve patient outcomes without the need for hypoxia-targeted drugs. This article will review the premise and underpinning evidence for personalized hypoxia-targeted dose painting. It will present data on relevant hypoxia imaging biomarkers, highlight the challenges and potential benefit of this approach and provide recommendations for future research priorities in this field. Person-alized hypoxia-based radiotherapy de-escalation strategies will also be addressed. Semin Radiat Oncol 33:298-306 & COPY; 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:298 / 306
页数:9
相关论文
共 50 条
  • [41] Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents
    Omran, Ziad
    Guise, Chris P.
    Chen, Linwei
    Rauch, Cyril
    Abdalla, Ashraf N.
    Abdullah, Omeima
    Sindi, Ikhlas A.
    Fischer, Peter M.
    Smaill, Jeff B.
    Patterson, Adam V.
    Liu, Yuxiu
    Wang, Qingmin
    MOLECULES, 2021, 26 (11):
  • [42] Phase I study of TH-302, investigational hypoxia-targeted drug, in combination with sunitinib.
    Starodub, Alexander
    Milhem, Mohammed M.
    Pennington, Kenneth Lee
    Kio, Ebenezer A.
    Bruetman, Daniel
    Thorne, Tracy
    Hickingbottom, Barbara
    Kroll, Stew
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] GLIOBLASTOMA TISSUE INVASION MAPPING WITH NOVEL HYPOXIA-TARGETED BLOOD OXYGENATION-LEVEL DEPENDENT MRI
    Stumpo, Vittorio
    Bellomo, Jacopo
    van Niftrik, Christiaan Hendrick Bas
    Sebok, Martina
    Kulcsar, Zsolt
    Weller, Michael
    Bink, Andrea
    Regli, Luca
    Fierstra, Jorn
    NEURO-ONCOLOGY, 2024, 26
  • [44] Sensitivity of Relative Cell Survival to Oxygen Enhancement Ratio in Fractionated Radiotherapy with Hypoxia Targeted Dose Escalation
    Chvetsov, A.
    Rajendran, J.
    Zeng, J.
    MEDICAL PHYSICS, 2017, 44 (06)
  • [45] Hypoxia-targeted and spatial-selective tumor suppression by near infrared nanoantenna sensitized engineered bacteria
    Tao, Chengcheng
    Miao, Xinxing
    Yan, Jun
    Xiao, Xiang
    Wu, Renfei
    Cao, Qinghua
    Wang, Zhexiang
    Lv, Rui
    Ge, Tianjin
    Liu, Jian
    ACTA BIOMATERIALIA, 2023, 170 : 442 - 452
  • [46] Estimating Dose Painting Effects in Radiotherapy: A Mathematical Model
    Lopez Alfonso, Juan Carlos
    Jagiella, Nick
    Nunez, Luis
    Herrero, Miguel A.
    Drasdo, Dirk
    PLOS ONE, 2014, 9 (02):
  • [47] A new plan quality index for dose painting radiotherapy
    Park, Yang-Kyun
    Park, Soyeon
    Wu, Hong-Gyun
    Kim, Siyong
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2014, 15 (04): : 316 - 325
  • [48] Radiotherapy dose painting by circadian rhythm based radiomics
    Abdollahi, Hamid
    MEDICAL HYPOTHESES, 2019, 133
  • [49] Dose Painting by Numbers Using Targeted Gold Nanoparticles
    Altundal, Y.
    Sajo, E.
    Korideck, H.
    Ngwa, W.
    MEDICAL PHYSICS, 2014, 41 (06) : 517 - 517
  • [50] Phase I study of TH-302, an investigational hypoxia-targeted drug, in combination with sunitinib.
    Starodub, Alexander
    Vaena, Daniel
    Pennington, Kenneth L.
    Kio, Ebenezer A.
    Bruetman, Daniel
    Thorne, Tracy
    Kroll, Stewart
    Milhem, Mohammed M.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)